Reversal of the Anti-platelet Effects of Ticagrelor
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the proportion of untreated donor platelets
required to fully reverse the platelet inhibitory effects of ticagrelor and aspirin in
healthy persons and patients with coronary artery disease undergoing percutaneous coronary
intervention (PCI) and receiving ticagrelor.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University